These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21807507)

  • 41. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
    Buckmelter AJ; Ren L; Laird ER; Rast B; Miknis G; Wenglowsky S; Schlachter S; Welch M; Tarlton E; Grina J; Lyssikatos J; Brandhuber BJ; Morales T; Randolph N; Vigers G; Martinson M; Callejo M
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1248-52. PubMed ID: 21211972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.
    Tang J; Hamajima T; Nakano M; Sato H; Dickerson SH; Lackey KE
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4610-4. PubMed ID: 18662874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
    Abraham S; Hadd MJ; Tran L; Vickers T; Sindac J; Milanov ZV; Holladay MW; Bhagwat SS; Hua H; Ford Pulido JM; Cramer MD; Gitnick D; James J; Dao A; Belli B; Armstrong RC; Treiber DK; Liu G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5296-300. PubMed ID: 21802948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
    Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
    J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Ballard P; Bradbury RH; Ducray R; Germain H; Hickinson DM; Hudson K; Kettle JG; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Pearson SE; Scott JS; Suleman A; Trigwell CB; Vautier M; Whittaker RD; Wood R
    Bioorg Med Chem Lett; 2008 Jan; 18(2):674-8. PubMed ID: 18061446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.
    Curtin ML; Frey RR; Heyman HR; Soni NB; Marcotte PA; Pease LJ; Glaser KB; Magoc TJ; Tapang P; Albert DH; Osterling DJ; Olson AM; Bouska JJ; Guan Z; Preusser LC; Polakowski JS; Stewart KD; Tse C; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2012 May; 22(9):3208-12. PubMed ID: 22465635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and biological evaluation of β-carboline derivatives as novel inhibitors targeting B-Raf kinase.
    Xin B; Tang W; Wang Y; Lin G; Liu H; Jiao Y; Zhu Y; Yuan H; Chen Y; Lu T
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4783-6. PubMed ID: 22704238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
    Dietrich J; Gokhale V; Wang X; Hurley LH; Flynn GA
    Bioorg Med Chem; 2010 Jan; 18(1):292-304. PubMed ID: 19962319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1
    Kim J; Choi B; Im D; Jung H; Moon H; Aman W; Hah JM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1314-1320. PubMed ID: 31307243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
    Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD
    Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potent and selective pyrazole-based inhibitors of B-Raf kinase.
    Hansen JD; Grina J; Newhouse B; Welch M; Topalov G; Littman N; Callejo M; Gloor S; Martinson M; Laird E; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4692-5. PubMed ID: 18676143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
    Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.
    Ducray R; Simpson I; Jung FH; Nissink JW; Kenny PW; Fitzek M; Walker GE; Ward LT; Hudson K
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4698-701. PubMed ID: 21775140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of quinazolinyloxy biaryl urea as a new class of SUMO activating enzyme 1 inhibitors.
    Kumar A; Ito A; Hirohama M; Yoshida M; Zhang KY
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5145-9. PubMed ID: 23920437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.
    Smith A; Ni ZJ; Poon D; Huang Z; Chen Z; Zhang Q; Tandeske L; Merritt H; Shoemaker K; Chan J; Kaufman S; Huh K; Murray J; Appleton BA; Cowan-Jacob SW; Scheufler C; Kanazawa T; Jansen JM; Stuart D; Shafer CM
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5221-5224. PubMed ID: 29107542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. B-Raf kinase inhibitors: hit enrichment through scaffold hopping.
    Gopalsamy A; Shi M; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2431-4. PubMed ID: 20307980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
    Ren L; Ahrendt KA; Grina J; Laird ER; Buckmelter AJ; Hansen JD; Newhouse B; Moreno D; Wenglowsky S; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Risom T; Sturgis HL; Voegtli WC; Mathieu S
    Bioorg Med Chem Lett; 2012 May; 22(10):3387-91. PubMed ID: 22534450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.
    Yin Y; Zheng K; Eid N; Howard S; Jeong JH; Yi F; Guo J; Park CM; Bibian M; Wu W; Hernandez P; Park H; Wu Y; Luo JL; LoGrasso PV; Feng Y
    J Med Chem; 2015 Feb; 58(4):1846-61. PubMed ID: 25621531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.